Zoetis Inc. Class A ($ZTS) Stock Forecast: Up 5.5% Today

What is Zoetis Inc. Class A?

Zoetis Inc. (ZTS) is a leading animal health company specializing in pharmaceuticals and vaccines for pets and livestock. Today, ZTS experienced a strong bullish movement in the stock market.

Why is Zoetis Inc. Class A going up?

ZTS stock is up 5.5% on Jun 9, 2026 16:26

• Concerns over slowing growth and a class action lawsuit may have impacted investor confidence initially, resulting in a drop in share price. However, the continued support of major investors like BLI Banque de Luxembourg Investments could have helped restore market confidence.
• Norges Bank's recent investment in Elanco Animal Health (ELAN) potentially signaled the attractiveness of the animal health sector, which may have positively influenced investor sentiment towards companies like Zoetis Inc.
• Analyst upgrades for companies like West Pharmaceutical Services (WST) and positive industry outlooks, such as for rail (CSX Corporation), may have contributed to a favorable market environment, benefiting ZTS as well.
• The approaching deadline for a securities class action lawsuit against SES AI Corporation (SES) may have spotlighted market risks, emphasizing the importance of strong fundamentals and growth potential, characteristics that companies like Zoetis Inc. demonstrate.

ZTS Price Chart

ZTS Technical Analysis

ZTS News

Zoetis Inc stock (US98978V1035): class action lawsuit and slowing growth unsettle investors

Zoetis Inc. is facing a securities class action lawsuit following a significant drop in share price due to concerns over slowing growth and guidance. The lawsuit alleges misleading statements regarding demand trends in key pet care categories. Despite these challenges, major investors like BLI Banque de Luxembourg Investments maintain sizable positions, highlighting the company's established animal health franchise amidst market reassessments.

https://www.ad-hoc-news.de/boerse/news/ueberblick/zoetis-inc-stock-us98978v1035-class-action-lawsuit-and-slowing-growth/69508308

Norges Bank Makes New $32.42 Million Investment in Elanco Animal Health Incorporated $ELAN

Norges Bank has initiated a new position in Elanco Animal Health (NYSE:ELAN), acquiring 1.43 million shares valued at about $32.42 million. This investment highlights increasing institutional interest in Elanco, which recently reported strong quarterly results and holds a "Moderate Buy" consensus rating from analysts.

https://www.marketbeat.com/instant-alerts/filing-norges-bank-makes-new-3242-million-investment-in-elanco-animal-health-incorporated-elan-2026-06-09/

Wolfe Research Says West Pharmaceutical Services (WST) is Positioned to Benefit from Injectable Drug Growth

Wolfe Research upgraded West Pharmaceutical Services (WST) to Outperform with a $375 price target, citing strong first-quarter performance and growth in GLP1-related products. Analyst Mike Polark believes WST is well-positioned due to its exposure to the expanding injectable drug market. Morgan Stanley also reaffirmed an "Equal Weight" rating with an increased price target of $325, noting management's conviction in future execution.

https://www.insidermonkey.com/blog/wolfe-research-says-west-pharmaceutical-services-wst-is-positioned-to-benefit-from-injectable-drug-growth-1777594/

Susquehanna Sees Improving Rail Demand, Raises CSX Target

Susquehanna has raised its price target for CSX Corporation (NASDAQ:CSX) to $50 from $44, reiterating a Neutral rating. This decision is based on improving rail demand, with volumes tracking ahead of expectations and encouraging ISM readings showing five consecutive months of expansion, indicating higher fuel prices are not hindering industrial demand. Additionally, BofA previously maintained a Buy rating on CSX and raised its price target to $51 after the company approved a $5 billion share repurchase program.

https://www.insidermonkey.com/blog/susquehanna-sees-improving-rail-demand-raises-csx-target-1777623/

SES UPCOMING DEADLINE: Levi & Korsinsky Alerts SES AI

Levi & Korsinsky, LLP reminds shareholders of SES AI Corporation (NYSE: SES) about an upcoming lead plaintiff deadline of June 26, 2026, in a securities class action lawsuit. The lawsuit alleges that SES shares collapsed due to delayed Q4 shipments and disappointing 2026 revenue guidance, costing shareholders $0.63 per share. Investors who purchased SES securities between January 29, 2025, and March 4, 2026, are encouraged to contact the firm to learn about their rights to potentially lead the class action.

https://www.globenewswire.com/news-release/2026/06/08/3308446/0/en/ses-upcoming-deadline-levi-korsinsky-alerts-ses-ai-corporation-stockholders-of-securities-class-action-contact-the-firm.html

Trending Today

Zoetis Inc. Class A Price History

08.04.2026 - ZTS Stock was down 7.6%

• Today, Zoetis (ZTS) experienced a significant bearish movement.
• Despite a positive outlook for a competitor in the animal health industry, Zoetis faced a bearish market movement.
• The overall U.S. stock market indexes closed down, with a stock noted as the stock that fell the furthest, indicating a broader negative sentiment in the market.
• Some companies saw rallies, while others experienced declines, showcasing mixed movements in the market that may have impacted Zoetis' stock price.
• Analysts estimating a decline in earnings and revenues for another company could have influenced overall sector sentiment, potentially affecting Zoetis' stock performance negatively.

08.04.2026 - ZTS Stock was down 6.9%

• Zoetis (ZTS) experienced a strong bearish movement today amidst a generally negative day for U.S. stock indexes, with the Dow Jones, S&P 500, and NASDAQ all closing in the red.
• The bearish trend in Zoetis' stock could be attributed to the broader market decline, as well as negative sentiment towards the healthcare sector.
• The ripple effect of another pharmaceutical company facing challenges in earnings and revenues might have impacted investor confidence in pharmaceutical companies, indirectly affecting Zoetis.
• Additionally, the focus on stocks hitting 52-week lows, including Zoetis, could have added to the selling pressure on the company's shares as investors reevaluated their positions in underperforming stocks.

13.01.2026 - ZTS Stock was up 6.6%

• Zoetis Inc. (ZTS) experienced a strong bullish movement today following its impressive Q4 earnings and optimistic 2026 guidance.
• The company reported Q4 revenue and adjusted EPS that exceeded estimates, showcasing strong financial performance.
• The positive market reaction can be attributed to Zoetis' solid financial results and optimistic outlook for future revenue and earnings growth, indicating investor confidence in the company's strategic direction and market positioning.
• This bullish momentum for Zoetis might have been further fueled by the overall positive sentiment in the animal health industry, as evidenced by institutional investments in related companies like Elanco Animal Health.

06.02.2026 - ZTS Stock was down 5.2%

• Zoetis Inc. (ZTS) witnessed a bearish market movement.
• The bearish trend could be linked to mixed results in the branded pharmaceutical sector, particularly highlighted in the Q4 earnings.
• While some companies like Bristol-Myers Squibb and Eli Lilly exceeded revenue expectations, the sector as a whole fell short of estimates, affecting investor sentiment.
• Moreover, a market report forecasting growth in the injected veterinary pain management drugs market may have raised concerns about potential competition for Zoetis Inc., influencing the negative market response.
• In conclusion, the underperformance of the sector combined with potential market challenges may have contributed to the bearish movement in Zoetis Inc. (ZTS) stock.

09.05.2026 - ZTS Stock was up 5.5%

• Concerns over slowing growth and a class action lawsuit may have impacted investor confidence initially, resulting in a drop in share price. However, the continued support of major investors like BLI Banque de Luxembourg Investments could have helped restore market confidence.
• Norges Bank's recent investment in Elanco Animal Health (ELAN) potentially signaled the attractiveness of the animal health sector, which may have positively influenced investor sentiment towards companies like Zoetis Inc.
• Analyst upgrades for companies like West Pharmaceutical Services (WST) and positive industry outlooks, such as for rail (CSX Corporation), may have contributed to a favorable market environment, benefiting ZTS as well.
• The approaching deadline for a securities class action lawsuit against SES AI Corporation (SES) may have spotlighted market risks, emphasizing the importance of strong fundamentals and growth potential, characteristics that companies like Zoetis Inc. demonstrate.

07.04.2026 - ZTS Stock was down 20.9%

• Zoetis (ZTS) stock might have experienced a bearish movement due to the broader market sentiment and company-specific factors.
• The negative market movement could be influenced by the news of other companies like Heron Therapeutics (HRTX) reporting a decline in earnings, potentially impacting investor confidence in the healthcare sector.
• Additionally, the focus on stocks hitting 52-week lows, including Zoetis, might have added to the bearish sentiment as investors reevaluate their positions based on fundamental company analysis.
• Overall, the combination of market dynamics, sector-specific news, and individual company performance could have contributed to Zoetis' bearish movement today.

07.04.2026 - ZTS Stock was down 22.5%

• Today's bearish movement in Zoetis (ZTS) stock can be attributed to a combination of factors:
• Analysts predicting a potential earnings beat for Zoetis' industry peer, Heron Therapeutics (HRTX), may have shifted investor focus away from Zoetis.
• Zoetis being mentioned with stocks hitting 52-week lows, despite its strong market position, could have raised concerns among investors about the company's short-term performance.
• Morningstar adjusting its long-term assumptions and valuation for Zoetis, although affirming its wide economic moat, might have prompted some investors to reassess their long-term investment thesis for the company.
• The general market sentiment towards the animal health industry, as indicated in Morningstar's analysis of Zoetis' market position and growth prospects, could have influenced the bearish movement in Zoetis stock today.

04.05.2026 - ZTS Stock was up 5.2%

• Despite legal challenges such as securities class action lawsuits and a previous stock value dip related to disclosures about its Companion Animal segment, Zoetis Inc. observed a positive market movement.
• The market's response could be attributed to potential institutional purchases and the company's proactive stance in addressing lawsuit concerns.
• Investors may be showing confidence in Zoetis' capacity to manage legal disputes and rebuild trust in its products and market position.
• The stock's upward trend might also be influenced by immediate market dynamics and speculative trades.

04.05.2026 - ZTS Stock was up 5.0%

• Despite facing multiple securities class action lawsuits alleging false and misleading statements regarding its Companion Animal segment, Zoetis Inc. (ZTS) saw a bullish market movement today.
• Investors may be optimistic about the company's ability to address the legal issues and maintain its market position.
• The bullish movement could also be attributed to positive developments in other segments of Zoetis' business or potential market opportunities that outweigh the current legal challenges.
• It's essential for investors to closely monitor how Zoetis navigates through these legal issues and the impact they may have on the company's financial performance in the future.

22.04.2026 - ZTS Stock was up 5.1%

• The bullish movement in Zoetis, Inc. (ZTS) stock today could be attributed to positive financial indicators and market sentiment:
• The increase in Return on Invested Capital and Return on Equity percentages may have signaled to investors that the company is utilizing its resources efficiently and generating good returns.
• The dilution adjustment announcement might have been perceived positively by investors, indicating potential strategic moves or capital restructuring that could benefit the company in the long run.
• The balance sheet showing growth in total assets and liabilities could have instilled confidence in the company's financial stability and growth prospects, leading to increased investor interest and driving the stock price higher.

11.04.2026 - ZTS Stock was down 5.3%

• Zoetis Inc (ZTS) experienced a strong bearish movement following the company's decision to lower its full-year guidance due to challenges in its U.S. companion animal business.
• Increased price sensitivity, fewer vet visits, and generic competition in the U.S. pet segment have contributed to the decline in Zoetis' stock price.
• The company is implementing strategic measures focusing on integrated solutions, cost controls, and operational efficiency to address the challenges in its pet segment while leveraging its more resilient livestock and international businesses.
• Despite the bearish movement, Zoetis Inc's long-term prospects in the animal health industry remain solid, with potential for recovery as the company executes its strategic reset.

11.04.2026 - ZTS Stock was down 5.0%

• Zoetis Inc (ZTS) faced a significant decline in its U.S. companion animal business, leading to a reset of its full-year guidance. This was primarily due to increased price sensitivity, reduced vet visits, and competition from generic products.
• The market reacted negatively to the lowered guidance, resulting in a bearish movement for ZTS stock.
• Despite the challenges in the U.S. pet segment, Zoetis is focusing on integrated solutions, cost controls, and operational efficiency to address the issues and leverage its more resilient livestock and international businesses.
• The bearish movement in ZTS stock today can be attributed to the concerns surrounding the company's U.S. pet business and the strategic reset to tackle these challenges.